Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | ATA3219 |
Trade Name | |
Synonyms | ATA 3219|ATA-3219 |
Drug Descriptions |
ATA3219 comprises allogeneic Epstein-Barr Virus (EBV)-targeted T-cells engineered to express a chimeric antigen receptor (CAR) targeting CD19, which potentially induce killing of CD19-expressing tumor cells and decrease tumor growth (Blood (2020) 136 (Supplement 1): 9). |
DrugClasses | CD19 Antibody 21 CD19 Immune Cell Therapy 65 |
CAS Registry Number | NA |
NCIT ID | NA |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
ATA3219 | ATA3219 | 0 | 1 |